Metsera (NASDAQ:MTSR) Earns Market Perform Rating from Leerink Partners

Key Points

• Metsera's stock received a "market perform" rating from Leerink Partners, with a revised target price of $57.00, down from $77.00, indicating a potential upside of 7.65% from its current price.
• Other analysts, including Cantor Fitzgerald and Bank of America, have issued "overweight" and "buy" ratings, suggesting a generally positive outlook with a consensus "Buy" rating and an average target price of $58.50.
• In the first quarter, several institutional investors, including Alphabet Inc. and T. Rowe Price, significantly increased their stakes in Metsera, reflecting growing confidence in the company's growth potential.

Metsera (NASDAQ:MTSR - Get Free Report)'s stock had its "market perform" rating reaffirmed by equities research analysts at Leerink Partners in a report issued on Wednesday,Benzinga reports. They presently have a $57.00 target price on the stock, down from their previous target price of $77.00. Leerink Partners' price objective suggests a potential upside of 7.65% from the stock's current price.

Other research analysts have also issued reports about the stock. Cantor Fitzgerald reissued an "overweight" rating on shares of Metsera in a research note on Wednesday, September 3rd. Bank of America raised their price target on shares of Metsera from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Thursday, August 28th. Guggenheim raised their price target on shares of Metsera from $56.00 to $62.00 and gave the stock a "buy" rating in a report on Tuesday, June 10th. Wells Fargo & Company initiated coverage on shares of Metsera in a report on Friday, June 20th. They set an "overweight" rating and a $65.00 price target for the company. Finally, Leerink Partnrs upgraded shares of Metsera to a "strong-buy" rating in a report on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, Metsera presently has a consensus rating of "Buy" and an average target price of $58.50.

Metsera Trading Down 0.1%

MTSR traded down $0.05 during trading on Wednesday, reaching $52.95. The company's stock had a trading volume of 391,190 shares, compared to its average volume of 1,277,682. The firm has a fifty day simple moving average of $35.91 and a two-hundred day simple moving average of $29.52. Metsera has a 1 year low of $12.30 and a 1 year high of $54.47.

Metsera (NASDAQ:MTSR - Get Free Report) last released its earnings results on Monday, July 28th. The company reported ($0.66) earnings per share for the quarter.

Institutional Investors Weigh In On Metsera

Several institutional investors have recently modified their holdings of the company. Alphabet Inc. purchased a new stake in shares of Metsera during the 1st quarter worth $135,059,000. T. Rowe Price Investment Management Inc. purchased a new stake in shares of Metsera during the 1st quarter worth $78,748,000. Wellington Management Group LLP purchased a new stake in shares of Metsera during the 1st quarter worth $65,382,000. Alpha Wave Global LP purchased a new stake in shares of Metsera during the 1st quarter worth $64,894,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Metsera during the 1st quarter worth $42,395,000.

Metsera Company Profile

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.